AAAAAA
Results:
1-19
|
Results: 19
Authors:
Skovsgaard, T
Davidson, NGP
Piccart, MJ
Richel, DJ
Bonneterre, J
Cirkel, DT
Barton, CM
Knight, S
Citation: T. Skovsgaard et al., A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer, ANN ONCOL, 12(9), 2001, pp. 1255-1257
Authors:
Nabholtz, JM
Bonneterre, J
Buzdar, A
Robertson, JFR
Thurlimann, B
Steinberg, M
Webster, A
von Euler, M
Citation: Jm. Nabholtz et al., Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Reply, J CL ONCOL, 19(9), 2001, pp. 2580-2582
Authors:
Adenis, A
Bonneterre, J
Bonneterre, ME
Pion, JM
Vanlemmens, L
Gladieff, L
de Lafontan, B
Martel, P
Mihura, J
Roche, H
Gedouin, D
Kerbrat, P
Lesimple, T
Bremond, A
Devaux, Y
Delecroix, V
Fumoleau, P
Maugard-Louboutin, C
Namer, M
Goudier, MJ
Morice, F
Montcuquet, P
Schraub, S
Coudert, B
Fargeot, P
de Gislain, C
Mayer, F
Bastit, P
Chevallier, B
Grandgirard, A
Monnier, A
Sun, X
Clavere, P
Ollivier, JP
Rhein, B
Roullet, B
Datchary, J
Audhuy, B
Barats, JC
Kohser, F
Dides, S
Ramos, R
Cattan, A
Eymard, JC
Pourny, C
Weber, B
de Laroche, G
Pichon, A
Seffert, P
Hayat, M
Zambon, E
Chollet, P
Van Praagh, I
Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611
Authors:
Fumoleau, P
Chauvin, F
Namer, M
Bugat, P
Tubiana-Hulin, M
Guastalla, JP
Delozier, T
Kerbrat, P
Devaux, Y
Bonneterre, J
Filleul, A
Clavel, M
Citation: P. Fumoleau et al., Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dosemitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes, J CL ONCOL, 19(3), 2001, pp. 612-620
Authors:
Bonneterre, J
Buzdar, A
Nabholtz, JMA
Robertson, JFR
Thurlimann, B
von Euler, M
Sahmoud, T
Webster, A
Steinberg, M
Citation: J. Bonneterre et al., Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma - Results of two randomized trials designed for combined analysis, CANCER, 92(9), 2001, pp. 2247-2258
Authors:
Kvinnsland, S
Anker, G
Dirix, LY
Bonneterre, J
Prove, AM
Wilking, N
Lobelle, JP
Mariani, O
di Salle, E
Polli, A
Massimini, G
Citation: S. Kvinnsland et al., High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment, EUR J CANC, 36(8), 2000, pp. 976-982
Authors:
Rougier, P
Adenis, A
Ducreux, M
de Forni, M
Bonneterre, J
Dembak, M
Clouet, P
Lebecq, A
Baille, P
Lefresne-Soulas, F
Blanc, C
Armand, JP
Citation: P. Rougier et al., A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma, EUR J CANC, 36(8), 2000, pp. 1016-1025
Authors:
Vergote, I
Bonneterre, J
Thurlimann, B
Robertson, J
Krzakowski, M
Mauriac, L
Koralewski, L
Webster, A
Steinberg, M
von Euler, M
Citation: I. Vergote et al., Randomised study of anastrozole versus tamoxifen as first-line therapy foradvanced breast cancer in postmenopausal women, EUR J CANC, 36, 2000, pp. S84-S85
Authors:
Fumoleau, P
Deporte, R
Kerbrat, P
Bonneterre, J
Fargeot, P
Citation: P. Fumoleau et al., UFT/leucovorin plus vinorelbine combination for advanced breast cancer, ONCOLOGY-NY, 14(10), 2000, pp. 50-55
Authors:
Alexandre, J
Bleuzen, P
Bonneterre, J
Sutherland, W
Misset, JL
Guastalla, JP
Viens, P
Faivre, S
Chahine, A
Spielman, M
Bensmaine, A
Marty, M
Mahjoubi, M
Cvitkovic, E
Citation: J. Alexandre et al., Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients, J CL ONCOL, 18(3), 2000, pp. 562-573
Authors:
Bonneterre, J
Thurlimann, B
Robertson, JFR
Krzakowski, M
Mauriac, L
Koralewski, P
Vergote, I
Webster, A
Steinberg, M
von Euler, M
Citation: J. Bonneterre et al., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study, J CL ONCOL, 18(22), 2000, pp. 3748-3757
Authors:
Mauriac, L
Bonneterre, J
Citation: L. Mauriac et J. Bonneterre, Aromatase inhibitors, B CANCER, 2000, pp. 5-5
Authors:
Harousseau, JL
Zittoun, R
Bonneterre, J
Hedouin, M
Ouvry, J
Citation: Jl. Harousseau et al., Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination, B CANCER, 87(6), 2000, pp. 491-497
Authors:
Hebbar, M
Revillion, F
Louchez, MM
Fournier, C
Bonneterre, J
Peyrat, JP
Citation: M. Hebbar et al., Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients, CLIN CANC R, 5(6), 1999, pp. 1427-1433
Authors:
Bonneterre, J
Spielman, M
Guastalla, JP
Marty, M
Viens, P
Chollet, P
Roche, H
Fumoleau, P
Mauriac, L
Bourgeois, H
Namer, M
Bergerat, JP
Misset, JL
Trandafir, L
Mahjoubi, M
Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439
Authors:
Bercez, C
Lebrun, T
Bonneterre, ME
Selke, B
Lenne, X
Bonneterre, J
Citation: C. Bercez et al., Advanced breast cancer: an evaluation of the cost of recurrence, B CANCER, 86(6), 1999, pp. 585-590
Authors:
Bonneterre, J
Dubois, JB
Citation: J. Bonneterre et Jb. Dubois, Ninteenth Forum on Oncology - May 30 and June 1, 1999 - Paris - Abstracts, B CANCER, 86(5), 1999, pp. 413-413
Authors:
Feutrie, ML
Bonneterre, J
Citation: Ml. Feutrie et J. Bonneterre, Aromatase inhibitors, B CANCER, 86(10), 1999, pp. 821-827
Authors:
Selke, B
Bercez, C
Lenne, X
Bonneterre, ME
Lebrun, T
Bonneterre, J
Citation: B. Selke et al., Adjuvant treatment for breast cancer assessment of the cost of the strategies, B CANCER, 85(11), 1998, pp. 961-966
Risultati:
1-19
|